OTC

LOOPShare Announces Extension of Convertible Debenture Term

Monday, September 20, 2021 - 10:00pm

Vancouver, British Columbia--(Newsfile Corp. - September 20, 2021) - LOOPShare Ltd. (TSXV: LOOP) (OTC: LPPPF) (FSE: 3KZ0) ("LOOPShare") announces that it and the lender have agreed to extend the maturity date for its outstanding $300,000 principal amount convertible debentures (the "Debentures") to the earlier of December 16, 2021 and the closing date of the previously announced transaction with VGAN Brands Inc.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - September 20, 2021) - LOOPShare Ltd. (TSXV: LOOP) (OTC: LPPPF) (FSE: 3KZ0) ("LOOPShare") announces that it and the lender have agreed to extend the maturity date for its outstanding $300,000 principal amount convertible debentures (the "Debentures") to the earlier of December 16, 2021 and the closing date of the previously announced transaction with VGAN Brands Inc.
  • In connection with the extension, the underlying detachable share purchase warrants (the "Warrants") will also have their maturity date extended to December 16, 2021.
  • Please refer to LOOPShare's press releases dated February 4, 2020, March 18, 2020 and March 19, 2020 for additional details on the terms of the Debentures and Warrants.

Maven Rebrands as The Arena Group, Expanding Business Strategy Around Consumer Media Verticals Anchored by Flagship Brands

Monday, September 20, 2021 - 9:01pm

This new identity celebrates the companys efforts over the past year to focus its core business strategy - building scalable media verticals, dubbed Arenas, on a dynamic single technical platform, around passionate consumer interests.

Key Points: 
  • This new identity celebrates the companys efforts over the past year to focus its core business strategy - building scalable media verticals, dubbed Arenas, on a dynamic single technical platform, around passionate consumer interests.
  • The Arena Group saw an opportunity to sharpen its focus around building high-performing flagship brands that could cross-pollinate value for publishers within each verticals ecosystem.
  • Recurring subscriptions across all of The Arena Groups properties now account for 55% of overall revenue.
  • Females now represent a quarter of the sports verticals audiences, up 42% since Sports Illustrated came under The Arena Group.

Founder Jeff Maser Steps Down as CEO and Director and Joins Advisory Board; Richard Gillis Appointed as President and Chief Operating Officer, Tinley USA and Joins Newly Created Office of The CEO

Monday, September 20, 2021 - 8:37pm

The Company also announces that Founder and CEO, Jeff Maser, has stepped down from his role as CEO and director and will join the Companys advisory board.

Key Points: 
  • The Company also announces that Founder and CEO, Jeff Maser, has stepped down from his role as CEO and director and will join the Companys advisory board.
  • Prior to joining Tinley, Rick Gillis served as General Manager, Coca-Cola Enterprises for the Southwest US.
  • In this capacity, Mr. Gillis oversaw thousands of employees in multiple bottling, distribution and sales facilities for one of the companys largest regional business units.
  • He subsequently served as President of Youngs Market Company which, under his tenure, was the second-largest beverage alcohol distributor in the Western USA.

LUCIRA™ HEALTH Hires Tony Allen as Chief Operations Officer

Monday, September 20, 2021 - 9:01pm

EMERYVILLE, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Lucira Health or Lucira) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced operations expert Tony Allen has joined the company as Chief Operations Officer.

Key Points: 
  • EMERYVILLE, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Lucira Health or Lucira) (NASDAQ: LHDX), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits, today announced operations expert Tony Allen has joined the company as Chief Operations Officer.
  • Allen comes to Lucira with 25 years experience in operations and management.
  • Lucira is a right place - right time - right tech healthcare company, said Allen.
  • Im looking forward to collaborating with the team to work towards increasing production, streamlining operations, and increasing product availability worldwide.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against China Evergrande Group and Encourages Investors with Losses to Contact the Firm

Monday, September 20, 2021 - 8:02pm

The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of China Evergrande Group (China Evergrande or the Company) (OTC: EGRNF , EGRNY ) for violations of the securities laws.

Key Points: 
  • The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of China Evergrande Group (China Evergrande or the Company) (OTC: EGRNF , EGRNY ) for violations of the securities laws.
  • The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
  • Years of aggressive borrowing have collided with Beijings crackdown on debt, leaving [China Evergrande] on the brink of collapse.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

Sustainable Green Team, Ltd. (SGTM) Acquires a Custom Potting Soil Production System, Diversifying its Product Offering

Monday, September 20, 2021 - 7:25pm

Mitchell Ellis Products Inc. was founded in 1977 and has provided machinery for potting soil, nursery, and greenhouse markets for over 44 years ( Learn more ).

Key Points: 
  • Mitchell Ellis Products Inc. was founded in 1977 and has provided machinery for potting soil, nursery, and greenhouse markets for over 44 years ( Learn more ).
  • The system is designed to have a nominal production rate of 120 cubic yards per hour.
  • This will allow SGTM to easily produce custom soil and substrate formulations for its internal research and development programs along with custom batches for growers and retail clients.
  • Sustainable Green Teams process is gentle and simply rubs the coir apart in a dry state, providing the ultimate product condition for soil blending or direct bagging.

Majority Stockholders of Coro Global Inc. Request a Special Meeting of Stockholders to Remove the Current Directors

Monday, September 20, 2021 - 6:07pm

It is time for meaningful changes at Coro Global, said Lou Naser, who previously served as an independent director and Chairman of the Board of Coro Global.

Key Points: 
  • It is time for meaningful changes at Coro Global, said Lou Naser, who previously served as an independent director and Chairman of the Board of Coro Global.
  • The full text of the letter is reproduced below:
    Dear Fellow Coro Global Stockholders:
    It is time for change and meaningful improvements at Coro Global.
  • Further damaging the Company, the current directors and management have engaged in self-dealing to line their own pockets at the expense of Coro Global stockholders.
  • Coro Global simply cannot afford continued mismanagement, lack of leadership and self-dealing by the current directors and management team.

Calissio Completes Its Application For Their Pink Sheet Current Information Tier With OTC Markets

Monday, September 20, 2021 - 5:10pm

PHOENIX, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Calissio Resources Group, Inc. (OTC PINK: CRGP) (the "Company") is pleased to announce they have completed its filing for their current up-listing to pink sheet current information tier with OTC Markets.

Key Points: 
  • PHOENIX, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Calissio Resources Group, Inc. (OTC PINK: CRGP) (the "Company") is pleased to announce they have completed its filing for their current up-listing to pink sheet current information tier with OTC Markets.
  • Once all the information submitted by the company has been reviewed, it is expected that Calissio will be upgraded to "Current Information" status.
  • The forward-looking statements in question are based on Calissio Resources Group, Inc.'s current expectations and projections about future events, based on information currently available.
  • Calissio Resources Group, Inc. disclaims any obligation to update any of its forward-looking statements, except as may be required by law.

New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space

Monday, September 20, 2021 - 5:53pm

VANCOUVER, BC, Sept. 20, 2021 /PRNewswire/ -- USA News Group - Oncology data leader COTA recently released a recent survey where half of the respondents pointed to "Operation Warp Speed" as evidence that cancer treatments can and should be moving forward faster. However, in many ways, 2021 has witnessed several major developments that continue to provide optimism within the oncology field, including those from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC),Roche Holding AG (OTC: RHHBY), Merck &. Co., Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: BMY), and Pfizer Inc. (NYSE: PFE).

Key Points: 
  • In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells.
  • In terms of significance, this effect was not seen with single-agent radiotherapy in either the primary or the abscopal tumors.
  • "This is a compelling finding that has the potential to be broadly applicable across multiple cancer indications and warrants further study.
  • As new Keytruda combinations from Merck emerge, Bristol-Myers Squibb has begun to tout 5-year kidney cancer data for Opdivo-Yervoy.

New Cancer Therapies Continue to Develop and Give Hope in Rapidly Improving Oncology Space

Monday, September 20, 2021 - 5:51pm

In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells.

Key Points: 
  • In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells.
  • In terms of significance, this effect was not seen with single-agent radiotherapy in either the primary or the abscopal tumors.
  • "This is a compelling finding that has the potential to be broadly applicable across multiple cancer indications and warrants further study.
  • As new Keytruda combinations from Merck emerge, Bristol-Myers Squibb has begun to tout 5-year kidney cancer data for Opdivo-Yervoy.